Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor by Sureda, Anna et al.
Bone Marrow Transplantation (2020) 55:613–622
https://doi.org/10.1038/s41409-019-0693-z
ARTICLE
Analysis of data collected in the European Society for Blood and
Marrow Transplantation (EBMT) Registry on a cohort of lymphoma
patients receiving plerixafor
Anna Sureda1 ● Christian Chabannon 2 ● Tamás Masszi3 ● David Pohlreich4 ● Christof Scheid5 ●
Catherine Thieblemont6 ● Björn E. Wahlin7 ● Ioanna Sakellari 8 ● Nigel Russell9 ● Andrea Janikova10 ●
Anna Dabrowska-Iwanicka11 ● Cyrille Touzeau12 ● Albert Esquirol13 ● Esa Jantunen14 ● Steffie van der Werf15 ●
Paul Bosman15 ● Ariane Boumendil16 ● Qianying Liu17 ● Marina Celanovic17 ● Silvia Montoto18 ● Peter Dreger19
Received: 14 February 2019 / Revised: 3 July 2019 / Accepted: 20 July 2019 / Published online: 30 September 2019
© The Author(s) 2019. This article is published with open access
Abstract
Plerixafor+ granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor
mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study
(NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization
versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between
comparison groups. The following mobilization regimens were compared: G-CSF+ plerixafor (G+ P) versus G-CSF alone;
G+ P versus G-CSF+ chemotherapy (G+ C); and G-CSF+ plerixafor+ chemotherapy (G+ P+ C) versus G+ C. The
primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR).
Overall, 313/3749 (8.3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score
matching, 70 versus 36 patients were matched in the G+ P versus G-CSF alone cohort, 124 versus 124 in the G+ P versus
G+ C cohort, and 130 versus 130 in the G+ P+ C versus G+C cohort. For both PFS and OS, the upper bound of
confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No
major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups.
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Lymphomas are the second most common indication for
autologous hematopoietic stem cell (HSC) transplantation
(HSCT). The most common method for mobilizing HSCs
from the peripheral blood is treatment with granulocyte-
colony stimulating factor (G-CSF) alone or combined with
chemotherapy [1, 2]. However, a sizable minority of
patients fail to mobilize sufficiently with G-CSF-based
regimens [3, 4].
Plerixafor has a mode of action different from other HSC
mobilizing agents and acts by binding to chemokine (C-X-C
motif) receptor 4 (CXCR4), preventing the binding of its
ligand stromal cell-derived factor 1 (SDF-1, now C-X-C
motif chemokine 12, CXCL12) and thereby inhibiting
events downstream of CXCL12 including SDF-1-mediated
G-protein activation, receptor internalization, calcium flux,
and chemotaxis [5, 6]. The CXCL12/CXCR4 interaction is
an integral part of the mechanism of homing and retention
of HSC in the bone marrow and inhibition of this interaction
by plerixafor mobilizes HSCs from the bone marrow [7, 8].
Unlike cytokines used for HSC mobilization (e.g., G-CSF),
plerixafor is not a growth factor and does not cause cell
proliferation or expansion. Therefore, the approved use for
plerixafor is in combination with G-CSF [9, 10].
As there is a theoretical risk of tumor cell mobilization
with any stem cell mobilization method for HSCT, the
European Medicines Agency requested a postapproval
analysis of plerixafor to evaluate the possible long-term
negative impact related to tumor cell mobilization.
The European Society for Blood and Marrow Trans-
plantation (EBMT) database is run and accessed through a
project manager internet server and is accessible to all
EBMT registered centers. Our analysis of the EBMT reg-
istry data for long-term clinical outcomes included
progression-free survival (PFS), overall survival (OS), and
cumulative incidence of relapse (CIR) in patients with
lymphoma. Patients who received plerixafor for mobiliza-
tion of HSCs were matched by propensity scoring with
patients who received other standard mobilization methods.




This was an international, multicenter, non-interventional
registry study, with patient follow-up ranging from 3.5 to
7.5 years, which evaluated the outcomes for patients with
lymphoma who received G-CSF+ plerixafor compared
with other mobilization methods for HSC mobilization and
who received an autologous HSCT (ClinicalTrials.gov
number NCT01362972). All patients ≥18 years from the
EBMT registry, with a diagnosis of lymphoma who were
considered poor mobilizers and had undergone their first
autologous HSCT between 2008 and 2012, were considered
eligible for the study. Patients in the plerixafor groups who
were poor mobilizers were those treated according to the
label. Patients enrolled in the registry and evaluated in this
study were from Austria, Belgium, Bulgaria, Czech
Republic, Finland, France, Germany, Greece, Hungary,
Ireland, Israel, Italy, Netherlands, Poland, Romania, Spain,
Sweden, Switzerland, and the United Kingdom.
The study was conducted in accordance with the
Declaration of Helsinki and the International Conference on
Harmonization Guidelines for Good Clinical Practice.
Approval of the protocol was obtained from all participating
sites, local governmental authorities, and Institutional
Review Boards. This was a non-inferiority study, with a
non-inferiority margin of a 30% increase in PFS and OS
corresponding to a hazard ratio (HR) upper bound of 1.3; no
lower limit was set.
Poor mobilizers
Predicted poor mobilizers were defined as patients who had
received prior irradiation to marrow bearing areas or had
high exposure to marrow-damaging chemotherapy. Proven
poor mobilizers were defined as patients who in a previous
mobilization attempt failed to mobilize sufficient CD34+
cells in peripheral blood to proceed to apheresis or to pro-
ceed to transplantation, or who, in the current mobilization,
failed to achieve a sufficient increase in peripheral blood
CD34+ cells at the predicted time for peak mobilization
[11]. In this study, only poor mobilizers (either predicted or
proven) have been considered in the propensity score
matching and analyses.
Data collection
The data were entered, managed, and maintained centrally
in an internet accessible database. Variables present on the
EBMT Minimum Essential Data A and B forms were used
to derive the data for the study and Medical C form was
used to obtain plerixafor data.
Outcomes
The primary efficacy outcomes were OS, PFS, and CIR.
Secondary efficacy outcomes were hematological recovery
(time to achieve absolute neutrophil counts of ≥0.5 × 109/L
and platelet counts of ≥50 × 109/L). All transplant compli-
cations occurring within 100 days of transplantation were
recorded.
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The following mobilization regimens were assessed:
● G-CSF+ plerixafor versus G-CSF alone;
● G-CSF+ plerixafor versus G-CSF+ chemotherapy;
● G-CSF+ plerixafor+ chemotherapy versus G-CSF+
chemotherapy.
Graft failure was defined as: (1) the loss of the graft with
neutrophils reaching ≥ 0.5 × 109 cells/L but subsequently
decreasing to a lower level of cells until additional treatment
for engraftment was provided, or (2) no engraftment, where
neutrophils never reached ≥0.5 × 109 cells/L.
Statistical analyses
Due to the observational nature of the study, no formal
statistical hypothesis testing was planned with adequate
power or Type 1 error control.
Propensity score method was used to identify study com-
parison groups that were balanced with respect to baseline
characteristics, including, demographics, lymphoma type,
disease characteristics and staging, prior treatment character-
istics, and disease status [12]. The baseline variables and
patient demographics used for propensity score matching are
shown in Table 1. Only patients who were identified as a
“proven or predicted poor mobilizer” were included in the
analysis.
A single imputation approach was implemented to create
complete data sets for analyses. Propensity scores were then
fit using logistic regression models. Matches for plerixafor
patients were identified from the non-plerixafor groups based
on the estimated propensity scores. Matching was performed
without replacement. Model success was based on whether
balance between the plerixafor and the control groups
matched samples was achieved.
Following the propensity score analysis, the outcomes
for each mobilization treatment group were analyzed for
comparable groups. Cox proportional hazards model with
covariates was used for OS and PFS. The 95% confidence
intervals (CI) and HR for the effect of treatment were cal-
culated. Potential covariates included: interval from diag-
nosis to transplantation, disease status at conditioning and
conditioning regimen, and disease status at time of
transplantation.
Survival curves were developed for each treatment
group using nonparametric Kaplan–Meier estimates [13],
as well as survival rates at 6 months, and at 1, 2, 3, 4, and
5 years.
A competing risk model was developed for CIR; death
without prior progression/relapse was treated as a compet-
ing event. The 95% CI and cumulative incidence at each
year post transplantation were estimated.
Sample size was estimated using the following
assumptions: 15% of transplanted lymphoma patients
would receive G-CSF alone and 85% would receive G-
CSF+ chemotherapy; 10% of patients transplanted from
each regimen would receive plerixafor treatment; and
70% of patients receiving plerixafor would be matched at
a ratio of 1:2 plerixafor to comparator.
Results
Participants and demographics
Overall, 3764 patients were screened and 3749 were
eligible to be included in the study (Fig. 1). These
included 140 patients treated with G-CSF+ plerixafor,
173 patients treated with G-CSF+ chemotherapy+
plerixafor, 549 patients treated with G-CSF alone, and
2887 patients treated with G-CSF+ chemotherapy. The
propensity score matching of predicted and proven poor
mobilizers identified matched groups for the comparative
analysis (Table 1). The number of patients classified as
predicted or proven poor mobilizers was 136 treated with
G-CSF+ plerixafor, 173 treated with G-CSF+ che-
motherapy+ plerixafor, 54 treated with G-CSF alone, and
245 treated with G-CSF+ chemotherapy.
After propensity scoring, 70 patients in the G-CSF+
plerixafor were matched with 36 patients in the G-CSF alone
cohort, 124 matched with 124 in the G-CSF+ plerixafor
versus G-CSF+ chemotherapy cohort, and 130 matched
with 130 in the G-CSF+ plerixafor+ chemotherapy versus
G-CSF+ chemotherapy cohort. Disease history and baseline
demographics of the patients are shown in Table 1.
The proportion of patients who were proven poor
mobilizers was greater in the plerixafor cohorts (ranging
from 97.1 to 98.4%) compared with the comparator cohorts
(ranging from 68.3 to 75.0%). More patients in the plerix-
afor groups failed to mobilize sufficient CD34+ cells at the
predicted peak mobilization time compared with patients in
the comparator groups (Table 2).
Primary outcomes
Progression-free survival
The estimated PFS at 3 years are shown in Table 3 and were
similar between comparison groups. The Kaplan–Meier
estimates for PFS were also similar for all the comparisons,
G-CSF+ plerixafor versus G-CSF alone (Fig. 2a), G-CSF+
plerixafor versus G-CSF+ chemotherapy (Fig. 2b), and
G-CSF+ plerixafor+ chemotherapy versus G-CSF+ che-
motherapy (Fig. 2c).
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Overall survival
Due to censoring median follow-up and interquartile ran-
ges were not calculable for some comparison groups.
Kaplan–Meier estimates of OS for the G-CSF+ plerixafor
versus the G-CSF alone group (comparison 1, Fig. 3a)
were similar. Similarly, Kaplan–Meier estimates of OS
for the G-CSF+ plerixafor group versus G-CSF+ che-
motherapy group (comparison 2, Fig. 3b) were also
similar, although the G-CSF+ plerixafor group trended
lower after 0.5 years compared with the G-CSF+ che-
motherapy group. For the G-CSF+ plerixafor+ che-
motherapy group compared with the G-CSF+
chemotherapy group OS was also similar between groups
(comparison 3, Fig. 3c). As the upper limit of the HR was
>1.3, based on predetermined boundaries, non-inferiority
of plerixafor was not demonstrated for any of the com-
parison groups. Estimated OS at 3 years are shown in
Table 3.
Cumulative incidence of relapse rates
Cumulative incidence of relapse rates at 3 years are shown
in Table 3. The CIR trended higher in the G-CSF alone
group compared with the G-CSF+ plerixafor group until
year 5. However, the CIR was similar between the
G-CSF+ plerixafor versus the G-CSF+ chemotherapy
group, and was similar between the G-CSF+ plerixafor+
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Secondary outcomes
Post transplantation
Adverse events occurring in more than one patient in any
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Fig. 2 Progression-free survival for each of the comparison groups, a
G-CSF+ plerixafor versus G-CSF alone (comparison 1); b G-CSF+
plerixafor versus G-CSF+ chemotherapy (comparison 2); and c G-
CSF+ plerixafor+ chemotherapy versus G-CSF+ chemotherapy
(comparison 3)
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shown in Table 4. Infections and infestations were the most
common standard organ class complication in all plerixafor
and comparator groups.
Engraftment was reported in ≥88% of patients in each
treatment group of the three comparisons. Similarly,
engraftment of both platelets and neutrophils was reported
in ≥82% of patients in each treatment group. The median
number of days to reach a platelet count of ≥20 × 109/L was
14 days for each of the plerixafor groups and 12–13 days
for the respective comparator groups. The median number
of days to reach a neutrophil count of ≥0.5 × 109/L was


















































































3 4 5 6 70.5
0 1 2
Time (years)
3 4 5 6 70.5
0 1 2
Time (years)






















































Plerixafor + G-CSF + chemo
G-CSF + chemo
Fig. 3 Overall survival for each of the comparison groups, a G-CSF+
plerixafor versus G-CSF alone (comparison 1); b G-CSF+ plerixafor
versus G-CSF+ chemotherapy (comparison 2); and c G-CSF+ pler-
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Fig. 4 Cumulative incidence of relapse for each of the comparison
groups, a G-CSF+ plerixafor versus G-CSF alone (comparison 1); b
G-CSF+ plerixafor versus G-CSF+ chemotherapy (comparison 2);
and c G-CSF+ plerixafor+ chemotherapy versus G-CSF+ che-
motherapy (comparison 3)
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Discussion
This study was a postapproval measure to investigate clin-
ical disease outcome as a surrogate of potential enhance-
ment of tumor cell release when combining G-CSF+
plerixafor. The study was not designed to evaluate the
benefit of stem cell mobilization with plerixafor compared
with other methods. In general, no major differences were
observed in PFS, OS, or CIR between the plerixafor and the
comparison groups.
In line with the plerixafor label all patients in the study
had to be poor mobilizers, either as proven poor mobilizers,
based on their mobilization history, or as predicted poor
mobilizers through exposure to high-dose chemotherapy.
However, despite propensity score matching, which tried to
balance the groups, there were still substantially more
proven poor mobilizers in the plerixafor cohorts, which may
have led to an imbalance between comparison groups.
Consistently the median pre-apheresis CD34+ cell counts
in the plerixafor cohorts during the current mobilization at
the predicted time of peak mobilization were lower com-
pared with comparison cohorts. Therefore, it appears that
the groups were not well balanced for disease and
HSCT risk.
Others have shown that lymphoma patients’ poor
mobilization of autologous stem cells, defined as the
inability to obtain ≥1 × 106 CD34+ cells/kg body weight,
resulted in substantially lower PFS and OS compared with
good mobilizers [14, 15]. Therefore, in our study, the higher
proportion of proven poor mobilizers in the plerixafor
groups may, at least in part, explain the PFS, OS, and CIR
results versus those in the comparison groups. Furthermore,
there are two confounders, which might have skewed the
analysis of the data in the current study. Firstly, poor
mobilization could be an indicator of more severe or
prognostically worse disease. Therefore, the post-plerixafor
outcomes trending toward slightly worse OS, PFS, and CIR
could be the result of more advanced lymphoma disease and
not a trend toward inferiority of plerixafor-mobilized grafts.
Secondly, data on the lymphoma biology were not avail-
able, which does not allow the confirmation that the pler-
ixafor and comparator groups were balanced in relation to
the stage of the lymphoma disease.
Engraftment was reported in ≥88% of patients in each of
the three comparator cohorts and the median number of
days to achieve the target levels of platelets and neutrophils
was similar for all cohorts (12–13 days and 11–12 days,
respectively), which was in line with findings from a pre-
vious study [16].
In support of our findings, results from a 5-year, long-
term, phase 3, follow-up study (not restricted to poor
mobilizers) suggested that the use of G-CSF+ plerixafor
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with lymphoma, with more than a half of patients with
lymphoma remaining alive 5 years post transplantation [17].
Propensity scores are increasingly used in non-
randomized studies to assess marginal treatment effects and
to reduce potential bias and imbalances of baseline cov-
ariates [12]. The assumption of propensity scores is that
none of the unmeasured covariates affecting treatment
choice confound the association between treatment and
outcome [18]. Unobserved differences between groups
cannot be adjusted by propensity scores; therefore, this is
both a source of potential bias and a limitation of propensity
scores [19]. Despite the modest sample size in the com-
parisons resulting from propensity scoring matching, in our
study, an adequate balance for certain key disease char-
acteristics collected in the database was maintained. How-
ever, we acknowledge that some key factors affecting
mobilization outcome were unavailable in the database,
such as, the number of rounds and the type of chemotherapy
administered, and for those who received radiotherapy the
extension of irradiated fields. These limitations in data
collection may have had a major impact on the outcomes in
our study.
Moreover, in line with the reimbursement criteria for
the drug and the obligation on some clinicians to closely
manage treatment costs [20], plerixafor may have been
selectively given to patients who were the poorest mobi-
lizers at highest risk, and this may have been a factor in
the trend for slightly worse outcomes in the plerixafor-
treated groups. Conversely, only patients with successful
mobilization were included in the study, this may have
inadvertently introduced selection bias in favor of the
non-plerixafor cohorts. Furthermore, our study was not
adequately powered, as there were small to moderate
numbers of patients in each cohort after propensity score
matching. Although every effort was made to remove
potential biases in this study, biases may not have been
removed completely due to the observational nature of
the data.
Conclusions
Although non-inferiority of the plerixafor groups could not
be formally shown, PFS, OS, and CIR were numerically
similar between comparators. Results from this study
should be interpreted with caution due to a number of
limitations. These include an imbalance between treatment
groups due to the greater proportion of proven poor mobi-
lizers in the groups treated with plerixafor, the limited scope
of the EBMT database, the lack of power, and the obser-
vational nature of the study. In particular, a higher pro-
portion of patients treated with plerixafor failed to mobilize
sufficient CD34+ cells at the predicted time. Therefore,
these patients represent a group that is likely predisposed to
worse outcomes. Infections and infestations were the most
common standard organ class posttransplant complication
for plerixafor and comparator cohorts. Without plerixafor
treatment, it is likely that some patients may not have
proceeded to transplantation. Altogether, this study does not
provide evidence that plerixafor mobilization is associated
with an increased risk of relapse or post-transplant toxicities
in patients undergoing HSCT for lymphoma.
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